Free Newsletter
FDA approves sBLA for BioThrax
The FDA has approved Emergent BioSolution's sBLA for BioThrax, the company's anthrax vaccine. The new approval changes the number of total vaccinnations that must be administered. It now calls for five intramuscular doses of BioThrax at 0, 1, 6, 12 and 18 months, compared with the former schedule of six subcutaneous doses at 0, 2 weeks and 1, 6, 12, 18 months. Emergent said the CDC is still studying whether even fewer doses of the drug could be equally effective. When that data becomes available in 2009, Emergent may submite another sBLA to further reduce the number of required BioThrax injections.
"Today's announcement is an exciting milestone in our continued mission to advance BioThrax. We are pleased that the U.S. Government shares our commitment to enhancing this critical countermeasure. The CDC is to be applauded for their hard work and diligence throughout this important effort," said Emergent's president and COO Daniel Abdun-Nabi.
- here's Emergent's release
Related Articles:
Emergent wins $404M anthrax vax contract
Emergent inks $29.7M anthrax vax contract
Emergent accuses biotech execs of wrecking buyout pact
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: